Genetic Testing for Long-QT Syndrome Distinguishing Pathogenic Mutations From Benign Variants

被引:260
作者
Kapa, Suraj [1 ]
Tester, David J. [2 ]
Salisbury, Benjamin A. [4 ]
Harris-Kerr, Carole [4 ]
Pungliya, Manish S. [5 ]
Alders, Marielle [6 ]
Wilde, Arthur A. M. [7 ]
Ackerman, Michael J. [1 ,2 ,3 ]
机构
[1] Mayo Clin, Div Cardiovasc Dis, Dept Med, Rochester, MN USA
[2] Mayo Clin, Windland Smith Rice Sudden Death Genom Lab, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA
[3] Mayo Clin, Div Pediat Cardiol, Dept Pediat, Rochester, MN USA
[4] PGxHealth LLC, New Haven, CT USA
[5] Genaissance Pharmaceut Inc, New Haven, CT USA
[6] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands
[7] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands
关键词
genetic testing; genetics; ion channels; long-QT syndrome; mutations; CARDIAC SODIUM-CHANNEL; GENOMIC ORGANIZATION; GENOTYPE; ARRHYTHMIAS; SUSCEPTIBILITY; PHENOTYPE; DIAGNOSIS; DISEASES; THERAPY; HERG;
D O I
10.1161/CIRCULATIONAHA.109.863076
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Genetic testing for long-QT syndrome (LQTS) has diagnostic, prognostic, and therapeutic implications. Hundreds of causative mutations in 12 known LQTS-susceptibility genes have been identified. Genetic testing that includes the 3 most commonly mutated genes is available clinically. Distinguishing pathogenic mutations from innocuous rare variants is critical to the interpretation of test results. We sought to quantify the value of mutation type and gene/protein region in determining the probability of pathogenicity for mutations. Methods and Results-Type, frequency, and location of mutations across KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3) were compared between 388 unrelated "definite" (clinical diagnostic score >= 4 and/or QTc >= 480 ms) cases of LQTS and >1300 healthy controls for each gene. From these data, estimated predictive values ( percent of mutations found in definite cases that would cause LQTS) were determined according to mutation type and location. Mutations were 10 times more common in cases than controls (0.58 per case versus 0.06 per control). Missense mutations were the most common, accounting for 78%, 67%, and 89% of mutations in KCNQ1, KCNH2, and SCN5A in cases and >95% in controls. Nonmissense mutations have an estimated predictive value >99% regardless of location. In contrast, location appears to be critical for characterizing missense mutations. Relative frequency of missense mutations between cases and controls ranged from approximate to 1:1 in the SCN5A interdomain linker to infinity in the pore, transmembrane, and linker in KCNH2. These correspond to estimated predictive values ranging from 0% in the interdomain linker of SCN5A to 100% in the transmembrane/linker/pore regions of KCNH2. The estimated predictive value is also high in the linker, pore, transmembrane, and C terminus of KCNQ1 and the transmembrane/linker of SCN5A. Conclusions-Distinguishing pathogenic mutations from rare variants is of critical importance in the interpretation of genetic testing in LQTS. Mutation type, mutation location, and ethnic-specific background rates are critical factors in predicting the pathogenicity of novel mutations. Novel mutations in low-estimated predictive value regions such as the interdomain linker of SCN5A should be viewed as variants of uncertain significance and prompt further investigation to clarify the likelihood of disease causation. However, mutations in regions such as the transmembrane, linker, and pore of KCNQ1 and KCNH2 may be defined confidently as high-probability LQTS-causing mutations. These findings will have implications for other genetic disorders involving mutational analysis. (Circulation. 2009;120:1752-1760.)
引用
收藏
页码:1752 / U31
页数:14
相关论文
共 29 条
[1]   Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: Implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing [J].
Ackerman, MJ ;
Splawski, I ;
Makielski, JC ;
Tester, DJ ;
Will, ML ;
Timothy, KW ;
Keating, MT ;
Jones, G ;
Chadha, M ;
Burrow, CR ;
Stephens, JC ;
Xu, CB ;
Judson, R ;
Curran, ME .
HEART RHYTHM, 2004, 1 (05) :600-607
[2]   Ethnic differences in cardiac potassium channel variants: Implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome [J].
Ackerman, MJ ;
Tester, DJ ;
Jones, GS ;
Will, ML ;
Burrow, CR ;
Curran, ME .
MAYO CLINIC PROCEEDINGS, 2003, 78 (12) :1479-1487
[3]  
Antonarakis SE, 1998, HUM MUTAT, V11, P1
[4]   A MOLECULAR-BASIS FOR CARDIAC-ARRHYTHMIA - HERG MUTATIONS CAUSE LONG QT SYNDROME [J].
CURRAN, ME ;
SPLAWSKI, I ;
TIMOTHY, KW ;
VINCENT, GM ;
GREEN, ED ;
KEATING, MT .
CELL, 1995, 80 (05) :795-803
[5]   A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes [J].
Easton, Douglas F. ;
Deffenbaugh, Amie M. ;
Pruss, Dmitry ;
Frye, Cynthia ;
Wenstrup, Richard J. ;
Allen-Brady, Kristina ;
Tavtigian, Sean V. ;
Monteiro, Alvaro N. A. ;
Iversen, Edwin S. ;
Couch, Fergus J. ;
Goldgar, David E. .
AMERICAN JOURNAL OF HUMAN GENETICS, 2007, 81 (05) :873-883
[6]   The complexities of predictive genetic testing [J].
Evans, JP ;
Skrzynia, C ;
Burke, W .
BMJ-BRITISH MEDICAL JOURNAL, 2001, 322 (7293) :1052-1056
[7]  
*GENETESTS, 1995, MED GEN INF RES DAT
[8]  
Grundy Scott M, 2004, J Am Coll Cardiol, V44, P720, DOI 10.1016/j.jacc.2004.07.001
[9]   Letting the genome out of the bottle - Will we get our wish? [J].
Hunter, David J. ;
Khoury, Muin J. ;
Drazen, Jeffrey M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (02) :105-107
[10]   LINKAGE OF A CARDIAC-ARRHYTHMIA, THE LONG QT SYNDROME, AND THE HARVEY RAS-1 GENE [J].
KEATING, M ;
ATKINSON, D ;
DUNN, C ;
TIMOTHY, K ;
VINCENT, GM ;
LEPPERT, M .
SCIENCE, 1991, 252 (5006) :704-706